These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3088221)

  • 1. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.
    Kurzrock R; Quesada JR; Talpaz M; Hersh EM; Reuben JM; Sherwin SA; Gutterman JU
    J Clin Oncol; 1986 Jul; 4(7):1101-9. PubMed ID: 3088221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
    Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
    Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of recombinant interferon gamma in cancer patients.
    Vadhan-Raj S; Al-Katib A; Bhalla R; Pelus L; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
    J Clin Oncol; 1986 Feb; 4(2):137-46. PubMed ID: 3080551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
    Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
    Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.
    Quesada JR; Kurzrock R; Sherwin SA; Gutterman JU
    J Biol Response Mod; 1987 Feb; 6(1):20-7. PubMed ID: 3104544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients.
    Boue F; Pastran Z; Spielmann M; Le Chevalier T; Subirana R; Sevin D; Paoletti C; Brandely M; Avril MF; Sancho-Garnier H
    Cancer Immunol Immunother; 1990; 32(1):67-70. PubMed ID: 2126985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
    Kurzrock R; Feinberg B; Talpaz M; Saks S; Gutterman JU
    J Interferon Res; 1989 Aug; 9(4):435-44. PubMed ID: 2502584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
    Maluish AE; Urba WJ; Longo DL; Overton WR; Coggin D; Crisp ER; Williams R; Sherwin SA; Gordon K; Steis RG
    J Clin Oncol; 1988 Mar; 6(3):434-45. PubMed ID: 3127550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
    Vadhan-Raj S; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
    Cancer Treat Rep; 1986 May; 70(5):609-14. PubMed ID: 3085930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I clinical trial of recombinant DNA gamma interferon.
    Brown TD; Koeller J; Beougher K; Golando J; Bonnem EM; Spiegel RJ; Von Hoff DD
    J Clin Oncol; 1987 May; 5(5):790-8. PubMed ID: 3106584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.
    Kurzrock R; Rosenblum MG; Quesada JR; Sherwin SA; Itri LM; Gutterman JU
    J Clin Oncol; 1986 Nov; 4(11):1677-83. PubMed ID: 3095504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
    Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
    J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
    Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
    Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
    Kurzrock R; Rosenblum MG; Sherwin SA; Rios A; Talpaz M; Quesada JR; Gutterman JU
    Cancer Res; 1985 Jun; 45(6):2866-72. PubMed ID: 3921249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ; Malspeis L; Young D; Neidhart JA
    J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
    J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I studies of recombinant interferon-gamma.
    Laszlo J; Goldstein D; Gockerman J; Hood L; Huang AT; Triozzi P; Sedwick WD; Koren H; Ellinwood EH; Tso CY
    J Biol Response Mod; 1990 Apr; 9(2):185-93. PubMed ID: 2160521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.